New and emerging treatment options for biliary tract cancer

Marcus S Noel
Aram F Hezel
James P Wilmot Cancer Center,
University of Rochester, Rochester, NY, USA

Abstract: Biliary tract cancer (BTC) is a group of relatively rare tumors with a poor prognosis. The current standard of care consists of doublet chemotherapy (platinum plus gemcitabine); however, even with cytotoxic therapy, the median overall survival is less than 1 year. The genetic basis of BTC is now more clearly understood, allowing for the investigation of targeted therapy. Combinations of doublet chemotherapy with antiepidermal growth factor receptor agents have provided modest results in Phase II and Phase III setting, and responses with small molecule inhibitors are limited. Moving forward as we continue to characterize the genetic hallmarks of BTC, a stepwise, strategic, and cooperative approach will allow us to make progress when developing new treatments.

Keywords: biliary tract cancer, cholangiocarcinoma, genetics, targeted therapy

Introduction

Biliary tract cancers (BTC) encompass a group of tumors, generally of the adenocarcinoma histologic subtype, that include both intra- and extrahepatic cholangiocarcinoma and gallbladder carcinoma. The incidence of BTC varies greatly throughout the world, ranging from as low as 0.1–0.2 individuals per 100,000 in Australia to 96 individuals per 100,000 in Thailand, and this rate is closely linked with the geographic distribution of risk factors. In the United States, it is estimated that more than 12,000 cases will be diagnosed in 2013, and the incidence of intrahepatic cholangiocarcinoma specifically appears to be on the rise. The high mortality of this disease is due to its late presentation, as the majority of patients come to clinical attention with metastatic disease; thus, less than 15% of patients are candidates for potential curative surgery.

Risk factors can be stratified based on location within the biliary tree. Specific risks for gallbladder cancer include large symptomatic gallstones, obesity, and the combination of chronic infection with Salmonella typhi and cholelithiasis. One of the strongest risk factors for cholangiocarcinoma is primary sclerosing cholangitis, with a lifetime risk in excess of 10%. Additional risk factors include bile duct adenoma, Caroli’s disease, multiple biliary papillomatosis, and infection with parasites (ie, Opisthorchis viverrini in Southeast Asia, and Clonorchis sinensis in Japan). Furthermore, diabetes and smoking are known independent risk factors for intrahepatic cholangiocarcinoma in addition to viral hepatitis. Gallbladder cancer is more common in females, whereas cholangiocarcinoma is seen more often in men and is likely secondary to the higher incidence of gallstones in females and primary sclerosing cholangitis in males. This review will highlight our current understanding of the genetic basis of BTC with an
in-depth focus on emerging targeted therapies as defined by each genetic subtype.

**Current standard of care**

Historically, progress in the discovery of new chemotherapeutic regimens for advanced BTC has been slow. One of the first randomized trials showed an overall survival (OS) benefit with 5-fluorouracil/leucovorin and etoposide compared to best supportive care with a median OS of 6 months versus 2.5 months, respectively; *P* < 0.01. As gemcitabine emerged as a treatment option for pancreatic cancer, providers begin to extrapolate its use to BTC, which was supported by Phase II trials of gemcitabine in advanced BTC, demonstrating response rates (RRs) greater than 20%. Combinations of cisplatin or oxaliplatin together with gemcitabine showed greater activity, as evidenced by comparatively improved RRs and progression-free survival (PFS) rates. This benefit of combination chemotherapy was firmly established by a randomized controlled trial of cisplatin and gemcitabine compared with gemcitabine alone. In the largest randomized biliary tract trial to date, 402 patients were enrolled between 2002 and 2004. OS was significantly increased in the combination arm versus with the single agent, gemcitabine (11.7 months versus 8.1 months). Based on these results, the combination of cisplatin and gemcitabine was established as the new standard of care in advanced, unresectable BTC. Additional clinical trials have evaluated oxaliplatin in combination with gemcitabine (GemOx) and have yielded similar PFS, OS, and RR to cisplatin/gemcitabine combinations. Given the favorable side effect profile, combined GemOx is a reasonable alternative.

Looking forward, ways to improve the outcome of patients with advanced disease may include incorporating novel “targeted” agents with traditional chemotherapy in order to maximize treatment efficacy and minimize the potential for toxicity, resulting in improved quality of life. This approach has been facilitated in other tumor types by understanding the genetic characteristics within each individual tumor that may predict responses to a defined molecular target. We will discuss the genetic features of BTC followed by the clinical trials attempting to capitalize on these mutations.

**Genetic basis of BTC**

The standard for genetic profiling of tumors is evolving. Previously, approaches for genotyping tumors were limited to single gene mutations or a select group of predefined mutations (ie, polymerase chain reaction, Sanger sequencing, and mass spectrometry-based assays). These techniques, however, come with limitations; among these is the fact that these techniques are insensitive for inactivating tumor suppressor mutations. As global, unbiased approaches such as whole genome sequencing have been utilized across many tumor types, previously unrecognized mutations have been uncovered. Thus, such comprehensive methods have not been applied to BTC; however, many genetic mutations in this disease have been uncovered and will be summarized (Table 1).

The complete genome of a number of cancer subtypes has been sequenced including pancreatic, esophageal, and lung cancer. With respect to cholangiocarcinoma, the complete spectrum of genetic mutations has yet to be defined, as the entire genome has not been sequenced. Efforts thus far have been limited to exome sequencing of the entire genome of eight well-characterized, liver fluke-associated tumors. Within this panel of tumors, 206 somatic mutations were identified in 187 genes using Sanger sequencing. The frequency of the most commonly mutated genes were *TP53* (44%), *KRAS* (17%) *SMAD4* (17%), and *MLL* (15%), which is similar to the results found in pancreatic cancer sequencing. Certainly, the limitation here is the inability to extrapolate results to other geographic regions where the incidence of liver fluke-associated cholangiocarcinoma is minimal.

Previous efforts analyzing the frequency of mutations in cholangiocarcinoma have established a wide range of alterations contributing to the heterogeneity of tumor pathogenesis. Mutations of the important mitogen-activated protein kinase intracellular signaling cascade with key effectors, RAS and RAF, are altered in BTC. Reported rates of *KRAS* mutations range from 9%–54% in intrahepatic tumors and 10%–22% in extrahepatic samples. Mutations in gallbladder carcinoma tend to be less frequent at 3%–38%.

Directly downstream from RAS, *B-RAF* mutations have changed the scope of metastatic melanoma. The range of mutations in BTC varies from 0%–20%. One particular series found *BRAF* to be mutated in approximately 20% of patients in both gallbladder and intrahepatic carcinomas.

<table>
<thead>
<tr>
<th>Gene</th>
<th>IHCC</th>
<th>EHCC</th>
<th>GB</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>KRAS</em></td>
<td>9%–54%</td>
<td>10%–22%</td>
<td>3%–38%</td>
<td>22–25</td>
</tr>
<tr>
<td><em>EGFR</em></td>
<td>10%–20%</td>
<td>5%–15%</td>
<td>9%–38%</td>
<td>33–36</td>
</tr>
<tr>
<td><em>PIK3A</em></td>
<td>5%–9%</td>
<td>4%</td>
<td>37, 38</td>
<td></td>
</tr>
<tr>
<td><em>BRAF</em></td>
<td>0%–22%</td>
<td>0%</td>
<td>0%–33%</td>
<td>26, 29</td>
</tr>
<tr>
<td><em>IDH1/IDH2</em></td>
<td>28%</td>
<td>7%</td>
<td>40–42</td>
<td></td>
</tr>
<tr>
<td><em>ERBB2/HER-2</em></td>
<td>0%–10%</td>
<td>5%–26%</td>
<td>16%</td>
<td>60</td>
</tr>
</tbody>
</table>

**Table 1 Common mutations in biliary tract cancer**

**Abbreviations:** IHCC, intrahepatic cholangiocarcinoma; EHCC, extrahepatic cholangiocarcinoma; GB, gallbladder carcinoma; HER-2, human epidermal growth factor receptor 2.
It should be noted that these particular mutations were found to be mutually exclusive of KRAS mutations.

The epidermal growth factor receptor (EGFR) and HER-2 NEU (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog [avian], also known as HER-2/NEU) are both involved in the pathogenesis of BTC. Overexpression of EGFR is found in 38%–100% of BTC. EGFR mutations of the tyrosine kinase domain have been found in intrahepatic and extrahepatic tumors (5%–15%) and in gallbladder carcinoma (9%–38%). The majority of these mutations were found in the gene sequence coding for the tyrosine kinase domain found in exon 21. The most common mutation in nonsmall cell lung carcinoma is found in codon 858; this study found only a silent nucleotide substitution in that codon.

Mutations of the PIK3CA/mammalian target of rapamycin signaling pathway have also been found in varying percentages of BTC samples, with frequencies ranging from 0%–33%. In addition to constitutively activated molecular pathways, dysregulated metabolic enzymes are a potential driver of oncogenesis. Somatic mutations in the isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) genes commonly found among human leukemia, glioblastoma, and sarcoma have recently been identified in subsets of biliary tract tumors. IDH1 and IDH2 are nicotinamide adenine dinucleotide phosphate-dependent enzymes that catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate. These somatic mutations lead to disruptive enzyme activity, allowing alpha-ketoglutarate to be more effectively converted to 2-hydroxyglutarate. Elevated levels of 2-hydroxyglutarate are hypothesized to promote carcinogenesis by competitively inhibiting enzymes that use alpha-ketoglutarate as a cofactor. Emerging data have identified that these mutations also occur in BTC; in one series of 87 patients with BTC, IDH mutations were found in 23% of intrahepatic cholangiocarcinoma samples. In another analysis of 94 tumors, mutations of IDH1 and IDH2 were found in 28% of intrahepatic samples, but only in 7% of extrahepatic tumors. One could postulate that the anatomic location of the tumor correlates to the genetic subtype; intrahepatic tumors have higher rates of IDH1/IDH2 mutations.

Clinical trials with targeted agents
The field of oncology has witnessed tremendous growth with respect to molecular targeted therapy within the last 10–15 years. While there have been significant breakthroughs in leukemia, lung cancer, and most recently melanoma, progress in BTC has lagged. Here, we will review a few key randomized clinical trials followed by a number of single-arm Phase II studies evaluating targeted agents in the first and setting line; an overview is provided in Table 2.

| Table 2 Phase II and Phase III clinical trials investigating targeted agents in BTC |
|---------------------------------|-----|-----|-------|-------|-------|-----|
| **EGFR** |     |     |       |       |       |     |
| GemOx ± erlotinib | 1st | III | 268   | 16% versus 30% | 4.2 versus 5.8 | 9.5 versus 9.5 | 43 |
| GemOx ± cetuximab | 1st | II  | 150   | 29% versus 23% | 5.3 versus 6 | 12.4 versus 11 | 44 |
| GemOx/cetuximab | 1st | II  | 30    | 63% | 8.8 | 15.2 | 45 |
| GemOx/cape/Pmab | 1st | II  | 46    | 33% | 8.3 | 10 | 48 |
| Gemlirino/Pmab | 1st | II  | 26/42 | 12.7 | 46 |
| Erlotinib | 2nd | II  | 42    | 8% | 2.6 | 7.5 | 65 |
| **VEGF** |     |     |       |       |       |     |
| GemOx/bevacizumab | 1st | II  | 35    | 40% | 7 | 12.7 | 53 |
| Sorafenib | 2nd | II  | 46    | 2% | 2.3 | 4.4 | 55 |
| Sorafenib | 1st | II  | 31    | 0% | 3 | 9 | 54 |
| Sunitinib | 2nd | II  | 56    | 8.9% | 4.8 | 56 |
| **MEK** |     |     |       |       |       |     |
| Selumitinib | 2nd | II  | 56    | 12% | 3.7 | 9.8 | 59 |
| HER-2 |     |     |       |       |       |     |
| Lapatinib | 2nd | II  | 17    | 0% | 1.8 | 5.2 | 61 |
| Combination |     |     |       |       |       |     |
| Erlotinib/bevacizumab | 1st | II  | 53    | 12% | 9.9 | 62 |
| Gemcitabine ± 5-FU | 1st | II  | 101   | 7.1 versus 4.2 | 12.5 versus 9 | 64 |

**Abbreviations**: BTC, biliary tract cancer; ORR, overall response rate; mPFS, median progression-free survival; mOS, median overall survival; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; GemOx, gemcitabine and oxaliplatin; HER-2, human epidermal growth receptor 2; cape, capecitabine; Pmab, panitumumab; Gemlirino, gemcitabine/irinotecan; MEK, mitogen-activated protein kinase.
EGFR

Both small molecule inhibitors of the kinase domain and antibodies targeting the extracellular components of EGFR have been evaluated in BTC. A randomized Phase III study conducted in South Korea investigated the combination of GemOx with or without erlotinib in advanced BTC.\(^4^3\) A total of 268 patients were recruited from eleven tertiary hospitals from 2009–2010. Although not statistically significant, an increase in PFS was seen, from 4.2 months in the chemotherapy-alone arm to 5.8 months in the combination group. There was a statistically significant increase in objective RR (16% versus 30%; \(P = 0.005\)); however, OS was equal in both groups at 9.5 months. A predefined subset analysis of patients specifically with intrahepatic cholangiocarcinoma revealed a greater increase in PFS for patients in the GemOx + erlotinib arm, suggesting that these patients may benefit from the addition of erlotinib. Mutation analysis was performed on 60 patient samples with adequate deoxyribonucleic acid for analysis; twelve patients (43%) were found to have overexpression of EGFR and six (10%) were found to have a \(KRAS\) mutation. Despite overexpression in limited samples, EGFR/\(KRAS\) is not an established predictive biomarker in BTC.

Cetuximab has long been approved for \(KRAS\) wild-type colon cancer, which raises interest in studying this antibody in BTC. A recently completed randomized Phase II trial (BINGO [A multicenter, randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with biweekly Cetuximab in the first-line treatment of advanced biliary cancer])\(^4^4\) was presented at American Society of Clinical Oncology 2012. From 2007–2009, 150 patients with advanced BTC were randomized to the combination of GemOx + erlotinib versus GemOx alone. The PFS and OS in the combination versus GemOx alone arm was 6.0 months versus 5.3 months, and 11.0 months versus 12.4 months, respectively. Furthermore, RRs in the GemOx + cetuximab arm were only 23% compared to 29% in the GemOx arm. Analysis of \(KRAS\) mutational status has just been completed; in the 91 patient samples adequate for deoxyribonucleic acid analysis, \(KRAS\) and \(BRAF\) mutations were found in 19% and 5% of patients, respectively.\(^4^4\) There was no statistically significant prognostic or predictive impact with respect to the \(KRAS\) mutation status, potentially explaining, to at least some degree, the lack of OS benefit with the addition of cetuximab.

In a smaller single-arm Phase II trial,\(^4^5\) 30 patients with advanced BTC were treated with the combination of GemOx and cetuximab. Results were notable for an objective response in 19 patients (63%), including three of whom achieved a complete response. Notably, nine initially unresectable patients were able to undergo surgical resection after response to treatment. Analysis of the tumors sample revealed \(KRAS\) mutations in 3/30 (10%); two of these patients had a partial response and the third had stable disease.

A recent Phase II randomized trial investigated GemOx + cetuximab versus GemOx alone.\(^4^7\) A total of 122 patients were enrolled; the PFS and OS in the GemOx + cetuximab arm versus the GemOx arm were 7.1 months versus 4.0 months, and 10.3 versus 8.8 months, respectively. Interestingly, subgroup analysis suggested that patients with \(KRAS\) mutated tumors derived benefit from cetuximab with increased PFS and OS of 7.0 months versus 1.9 months, and 10.3 months versus 6.6 months, respectively. This is surprising given the known and well established paradigms of \(KRAS\) mutation and its effect on EGFR therapy in colorectal cancer. It is possible that this result may be explained by the small sample size and potential variability in Phase II trials. An alternative explanation is that undiscovered features drive or contribute to response to anti-EGFR therapy in BTC as well.

Similar to the mechanism of action of cetuximab, panitumumab differs from cetuximab only in the fact that it is a fully humanized antibody as opposed to a chimeric antibody. A recent trial\(^4^8\) evaluated the combination of GemOx, capecitabine, and panitumumab. A total of 46 patients were enrolled at a single institution; importantly, this was the first “\(KRAS\) marker driven trial,” excluding patients who are \(KRAS\) mutant.\(^4^8\) The RR was 33%, the PFS was 8.3 months, and the median OS was 10 months.

The chemotherapeutic backbone of gemcitabine and irinotecan is much less studied in BTC; nonetheless, the combination was evaluated with panitumumab in a Phase II study that remains open for accrual.\(^4^6\) To date 26/42 patients have been enrolled with nine objective responses, including three complete responses in 21 evaluable patients. The median OS is 12.7 months; there have been no treatment-related deaths.

VEGF

The vascular endothelial growth factor (VEGF) is the most potent angiogenic factor currently identified.\(^5^0\) The entire family consists of six members, of which VEGF-A is the most extensively studied. Binding of VEGF to its receptor leads to activation of key downstream cellular signaling molecules. Approved in 2004, bevacizumab is indicated for use in the treatment of metastatic colon cancer,\(^5^1\) which is in addition to more recent approvals for use in nonsmall cell lung cancer,
MEK

The RAS/RAF/MEK/ERK pathway has been demonstrated to be constitutively activated in a wide variety of tumors including BTC. Activated RAS triggers phosphorylation and activation of RAF kinase, which subsequently phosphorylates MEK 1 and MEK 2, leading to the activation of ERK-1 and ERK-2. Phosphorylated ERK translocates into the nucleus where it activates key cellular functions. As ERK-1 and ERK-2 are the only known MEK substrates, MEK has been identified as a logical target of inhibition, and in a number of studies, both in vitro and in vivo systems have established the importance of MEK as a cancer target. Based on this rationale, a multi-institutional Phase II study evaluated the MEK inhibitor, selumetinib, in 28 patients as a second-line therapy in patients with metastatic BTC. The overall RR was 12%; additionally, 17 patients (68%) had stable disease leading to a disease control rate of 80%. Furthermore, the median PFS was 3.7 months and the OS was 9.8 months, which are greater than the rates observed in historical controls.

HER-2/NEU

Yet another key extracellular receptor with genetic relevance to BTC is HER-2/NEU, which is most extensively studied and clinically applicable in breast cancer. Lapatinib is a dual small molecule inhibitor of both HER-2/NEU and EGFR. A Phase II trial was performed in hepatocellular carcinoma and BTC with lapatinib as a single agent in the second line. In 17 patients with BTC, there were no objective responses seen; the median PFS was 1.8 months and the OS was 5.2 months.

Combinations

Both EGFR overexpression and angiogenesis have been associated with poor outcomes in BTC; thus, a combination approach was trialed in the Phase II setting as first-line therapy. A total of 53 patients were evaluated with the combination of erlotinib and bevacizumab between 2006 and 2008. In 49 evaluable patients, the objective RR was 12% and median OS was 9.9 months. Compared to the standard of care, these results are underwhelming; however, there may be a role for future combinations with cytotoxic chemotherapy.

A promising novel combination is that of gemcitabine plus S-1, an oral drug that combines three pharmacological agents: tegafur, a prodrug of 5-fluorouracil; 5-chloro-2,4-dihydroxypridine, which inhibits dihydroxypridine dehydrogenase activity; and potassium oxonate, which reduces gastrointestinal toxicity. In a Phase II trial, gemcitabine + S-1 (GS) was compared to single agent S-1. A total of 51 patients were randomized to the combination arm and 50 patients were randomized to the S-1 arm from 2009 to 2010. The median PFS was 7.1 months and 4.2 months, and the OS was 12.5 months versus 9.5 months in the combination arm. Despite the addition of bevacizumab, toxicity was quite manageable with no grade 3 or grade 4 bleeding events documented.

Sorafenib has been investigated as a first-line and second-line therapy in BTC. In a Phase II multi-institutional trial among 31 evaluable patients, there were no confirmed objective responses. Ten patients (32%) were documented as having stable disease; the median PFS was 3 months and the OS was 9 months. There was a high rate of grade 3/4 toxicities reported in this trial, including thromboembolism, hand–foot syndrome, and hyperbilirubinemia.

The use of sorafenib as a single agent after disease progression on standard therapies demonstrated minimal activity with an objective RR of 2%, a PFS of 2.3 months, and an OS of 4.4 months.

Sunitinib is yet another orally administered inhibitor of multiple tyrosine kinases, including VEGF, which has shown activity in a number of cancers including renal cell carcinoma. In an open label Phase II, single-arm, multicenter trial, sunitinib was evaluated as a second-line treatment. A total of 56 patients were evaluated; the objective RR was 8.9%. The median duration of disease control was 2.4 months and the median OS was 4.8 months. Toxicity was notable for greater than 46% of patients experiencing a grade 3 or grade 4 adverse event; thus, combined with marginal efficacy, the role of sunitinib in BTC is limited.

Table 3 Clinical trials currently enrolling in BTC

<table>
<thead>
<tr>
<th>Drug</th>
<th>Target</th>
<th>Phase of development</th>
<th>NCT number</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIBW-2992</td>
<td>HER-2/EGFR</td>
<td>I</td>
<td>01679405</td>
</tr>
<tr>
<td>MK-2206</td>
<td>AKT</td>
<td>II</td>
<td>01425879</td>
</tr>
<tr>
<td>ARRY-438162</td>
<td>MEK</td>
<td>I</td>
<td>00959127</td>
</tr>
</tbody>
</table>

Abbreviations: BTC, biliary tract cancer; NCT, National Clinical Trial; HER-2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; AKT, protein kinase B; MEK, mitogen-activated protein kinase.
concluded that GS warrants head-to-head comparisons with gemcitabine/cisplatin in a randomized Phase III trial.

In summary, there have been two randomized controlled trials with targeted agents, namely GemOx + erlotinib and GemOx + cetuximab with RRs nearing 30%; however, neither of these combination treatments led to a significant increase in OS. Phase II studies in the first- and second-line have yielded modest results, highlighting the drive for emerging targets.

**Future direction**

Given the favorable RR of selumetinib in the second-line setting, additional testing of MEK inhibition in BTC is worthwhile. Last year, the MEK inhibitor trametinib was shown to have a statistically significant increase in OS in metastatic melanoma when compared to standard chemotherapy; thus, early phase testing of this molecule in BTC is feasible. There are no completed trials investigating PIK3CA inhibition in BTC; however, two trials are evaluating inhibitors, BYL719 and SF1126.

Yet another promising oncologic target is c-met, which is a high-affinity receptor for hepatocyte growth factor. In addition, c-met activates the EGFR pathway, which is known to be upregulated in BTC, as discussed previously. In one series, c-met was found to be expressed in 35% of cases. In another series, immunohistochemical analysis of c-met in patient BTC samples revealed that tumors with a high level of c-met expression tended to have a worse prognosis. C-met inhibitors are in development and vandetanib has been approved for advanced medullary thyroid cancer; these agents are yet to be evaluated in vivo in BTC.

Preclinical data using IDH1/IDH2 inhibitors are emerging in leukemia and malignant glioma; given the frequency of mutations in cholangiocarcinoma, this is promising. Additional targets and enrolling trials are depicted in Table 3 and Figure 1.

**Conclusion**

Treatment for advanced BTC is currently anchored by the backbone of platinum-based doublet chemotherapy, which has a proven survival benefit. The genetic heterogeneity of this disease combined with its lower incidence as compared with other more common genetically heterogeneous tumor types (lung, colon, and breast cancer) has hindered progress in the development of novel targeted therapy. Our efforts should be focused on identifying those patients who would
best benefit from specific targeted agents in collaborative efforts. The first step is to more clearly define the complete mutational and genetic spectrum, which can be accomplished via whole genome efforts, as demonstrated in lung cancer. From there, predictive biomarkers can be established in order to maximize clinical response for each individual patient, essentially defining the model of “personalized medicine.” A stepwise, strategic, and cooperative approach will allow us all to make progress when developing new treatments.

Disclosure

Aram F Hezel serves as a consultant to Amgen and Bayer, and receives research funding from Amgen. The other author reports no conflicts of interest in this work.

References


